171.00p+9.30 (+5.75%)17 Sep 2021, 16:35
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.
Jump to:

Synairgen PLC Fundamentals

Company NameSynairgen PLCLast Updated2021-09-17
Shares in Issue201.342 mMarket Cap£344.29 m
PE Ratio0.00Dividend per Share0
Dividend Yield0Dividend Cover0
EPS-£0.09EPS Growth (%)0
PEG0DPS Growth (%)0
Debt Ratio0.0014Debt Equity Ratio0
Asset Equity Ratio1.0400Cash Equity Ratio0.8806
Quick Ratio24.5955Current Ratio25.88
Price To Book Value4.0437ROCE0

Synairgen PLC Dividends

TypeEx-DatePay DateCurrencyNet DividendYear Total

Synairgen PLC Company Financials

Tangible Assets£344,000.00£556,000.00£374,000.00
Intangible Assets£44,000.00£16,000.00£29,000.00
Total Fixed Assets£388,000.00£572,000.00£403,000.00
Debtors£8.82 m£96,000.00£135,000.00
Cash & Equivalents£74.98 m£2.45 m£5.33 m
Other Assets000
Total Assets£88.55 m£4.07 m£6.80 m
Creditors within 1 year£3.41 m£1.69 m£777,000.00
Creditors after 1 year0£127,000.000
Other Liabilities000
Total Liabilities£3.41 m£1.82 m£777,000.00
Net assets£85.14 m£2.25 m£6.03 m
Called up share capital£2.00 m£1.09 m£1.09 m
Share Premium£125.25 m£28.26 m£28.26 m
Profit / Loss-£17.73 m-£4.79 m-£4.10 m
Other Equity£85.14 m£2.25 m£6.03 m
Preference & Minorities000
Total Capital Employed£85.14 m£2.25 m£6.03 m
Debt Ratio0£0.050
Assets / Equity1.04001.04001.0400
Cash / Equity0.88060.88060.8806
Cash Flow202020192018
Cash from operating activities-£23.82 m-£2.90 m-£3.82 m
Cashflow before financing£72.57 m-£2.90 m-£1.15 m
Increase in Cash£72.52 m-£2.83 m£439,000.00
Cost of sales000
Gross Profit000
Operating Profit-£17.74 m-£4.82 m-£4.13 m
Pre-Tax profit-£17.73 m-£4.79 m-£4.10 m

Synairgen PLC Company Background

ActivitiesSynairgen PLC is a United Kingdom-based respiratory drug discovery and development company. The company is engaged in the drug discovery and development of therapies for respiratory diseases, particularly in the areas, including severe asthma, kidney fibrosis, cardiac fibrosis, chronic obstructive pulmonary disease, and idiopathic pulmonary fibrosis. The company's Programmes include SNG001, SG016, LOXL2 inhibitor, and others.
Latest Interim Date29 Sep 2021
Latest Fiscal Year End Date12 May 2021

Synairgen PLC Directors

2021-06-07Mr. Iain Peter Murray BuchananNon-Executive Director
2021-06-07Mr. Simon James Blouet ShawNon-Executive Director,Chairman
2021-06-07Dr. David Bruce CampbellNon-Executive Director
2021-08-19Mr. Richard James MarsdenExecutive Director,Chief Executive Officer
2021-06-07Professor Stephen Townley Holgate, CBENon-Executive Director
2021-08-19Dr. Phillip David MonkExecutive Director,Chief Scientific Officer
2019-06-03Mr. Paul Hugh Anthony CleggNon-Executive Director
2021-08-19Mr. John Christopher WardExecutive Director,Finance Director and Company Secretary

Synairgen PLC Contact Details

Company NameSynairgen PLC
AddressMailpoint 810, Level F, South Block, Southampton Gen Hospital, Tremona Road, Southampton, SO16 6YD
Telephone+44 2380512800

Synairgen PLC Advisors

SolicitorFladgate LLP
Phone+44 2030367000
Fax+44 2030367600
RegistrarCapita Asset Services
Phone+44 8716640300
Fax+44 2086392342
Financial PR AdviserConsilium Strategic Communications
Phone+44 2037095700
Remuneration ConsultantFIT Remuneration Consultants LLP
Phone+44 2070311111
Nominated AdviserFinnCap
Phone+44 2072200500
Fax+44 2076001659
Phone+44 2072200500
Fax+44 2076001659
AuditorBDO LLP
Phone+44 2380881700
Fax+44 2380881701